Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Scribd Logo
Upload

Welcome to Scribd!

  • 115 views

    Denosumab

    Uploaded by

    Mahdy AlShammari
    Prolia (denosumab) is a monoclonal antibody that binds to RANKL, inhibiting osteoclast formation and bone resorption. It increases bone mass in patients with high fracture risk from cancer treatment. Denosumab reaches maximum levels within 10 days via subcutaneous injection, with minimal metabolism and similar pharmacokinetics between genders, ages, and disease states. Treatment reduces bone resorption by 85% within 3 days. Osteonecrosis of the jaw has been reported, so dental exams are recommended before and during treatment.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    Denosumab

    Uploaded by

    Mahdy AlShammari
    115 views2 pages
    Prolia (denosumab) is a monoclonal antibody that binds to RANKL, inhibiting osteoclast formation and bone resorption. It increases bone mass in patients with high fracture risk from cancer treatment. Denosumab reaches maximum levels within 10 days via subcutaneous injection, with minimal metabolism and similar pharmacokinetics between genders, ages, and disease states. Treatment reduces bone resorption by 85% within 3 days. Osteonecrosis of the jaw has been reported, so dental exams are recommended before and during treatment.

    Original Description:

    Denosumab

    Original Title

    denosumab

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Prolia (denosumab) is a monoclonal antibody that binds to RANKL, inhibiting osteoclast formation and bone resorption. It increases bone mass in patients with high fracture risk from cancer treatment. Denosumab reaches maximum levels within 10 days via subcutaneous injection, with minimal metabolism and similar pharmacokinetics between genders, ages, and disease states. Treatment reduces bone resorption by 85% within 3 days. Osteonecrosis of the jaw has been reported, so dental exams are recommended before and during treatment.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    115 views2 pages

    Denosumab

    Uploaded by

    Mahdy AlShammari
    Prolia (denosumab) is a monoclonal antibody that binds to RANKL, inhibiting osteoclast formation and bone resorption. It increases bone mass in patients with high fracture risk from cancer treatment. Denosumab reaches maximum levels within 10 days via subcutaneous injection, with minimal metabolism and similar pharmacokinetics between genders, ages, and disease states. Treatment reduces bone resorption by 85% within 3 days. Osteonecrosis of the jaw has been reported, so dental exams are recommended before and during treatment.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    You are on page 1of 2

     Definition of the drug:

    Prolia (denosumab) is a monoclonal antibody, monoclonal antibodies are made to target and destroy only certain cells in the
    body, this may help to protect healthy cells from damage.

    Denosumab is used to increase bone mass in women and men with a high risk of bone fracture caused by receiving treatments
    for certain types of cancer.

     Mechanism of action:

    Denosumab binds to RANKL, a transmembrane or soluble


    protein essential for the formation, function, and survival of
    osteoclasts, the cells responsible for bone resorption,
    Denosumab prevents RANKL from activating its receptor
    "RANK" on the surface of osteoclasts , this will
    inhibit osteoclast formation, function, and survival, by that
    decreasing bone resorption and increasing bone mass and
    strength in both cortical and trabecular bone.

     Pharmacodynamics:
    In clinical studies, treatment with 60 mg of Prolia resulted in
    reduction in the bone resorption by approximately 85% by 3
    days, with maximal reductions occurring by 1 month. After
    discontinuation of Prolia treatment, markers of bone
    resorption increased to levels 40% to 60% above pretreatment
    values but returned to baseline levels within 12 months.
     Pharmacokinetics:

    Absorption: For a 60 mg subcutaneous dose, maximum serum denosumab concentrations (Cmax) of 6 μg/ml occurred in 10
    days.

    Biotransformation: Denosumab is composed solely of amino acids and carbohydrates as native immunoglobulin and is
    unlikely to be eliminated via hepatic metabolic mechanisms. Its metabolism and elimination are expected to follow the
    immunoglobulin clearance pathways, resulting in degradation to small peptides and individual amino acids.

    Denosumab pharmacokinetics was not affected by the formation of binding antibodies to denosumab and was similar in men
    and women. Age , race and disease state (low bone mass or osteoporosis; prostate or breast cancer) do not appear to
    significantly affect the pharmacokinetics of denosumab.

     Oral manifestations
    Osteonecrosis of the Jaw (ONJ): ONJ, which can occur spontaneously, is generally associated with tooth extraction, and has
    been reported in patients receiving Prolia "denosumab" .

    An oral exam should be performed by the prescriber prior to initiation of Prolia.

    Good oral hygiene should be maintained during treatment with Prolia.

    Patients who are suspected of having or who develop ONJ should receive care by a dentist.

     References:
     https://www.medicines.org.uk/emc/medicine/23127
     http://www.proliahcp.com/who-to-treat/range/index.html
     http://www.rxlist.com/prolia-drug/clinical-pharmacology.htm
     https://www.drugs.com/prolia.html

    Done by: Mahdi Jamal AlShammari , University number: 20142050282 , Seat: 19 , Day: Monday

    You might also like